Key Milestones for Moderna

2016

 
  • Lease signed to build 200,000 sq ft GMP mRNA clinical manufacturing facility in Norwood, Mass. - Set to open in early 2018
  • BARDA funding award for up to $125M for Zika
 
  • $474M equity financing (including $20M convertible note from Vertex)
  • Vertex CFTR collaboration - $40M upfront, one target ($20M cash payment, $20M convertible note investment)
  • Merck partnership in personalized cancer vaccines - $200M upfront
  • Charles River Laboratories (CRL) collaboration
  • Moderna initiates second FIH clinical study – Infectious disease vaccine mRNA 1851
  • Bill & Melinda Gates Foundation grant for HIV/AIDS - Up to $100M
  • Merck licenses additional vaccine candidate
  • AstraZeneca 50/50 collaboration in immuno-oncology - Two targets
  • Pharmaceutical Product Development, LLC (PPD) collaboration

2015

  • Moderna initiates first-in-human (FIH) clinical study – Infectious disease vaccine mRNA 1440
  • Personalized cancer vaccine venture Caperna launched
  • Rare disease venture Elpidera launched
  • Merck collaboration in infectious disease - $50M upfront, $50M equity, five targets
  • Infectious disease venture Valera launched
 
  • $450M equity financing

2014

  • Oncology venture Onkaido launched
  • Alexion strategic agreement in rare disease - $100M upfront, up to 10 targets

2013

 
  • $110M equity financing
 
  • Expansion to new HQ and labs at 200 Technology Sq.
  • DARPA grant - Up to $25M
  • AstraZeneca collaboration in cardiometabolic disease and cancer - $240M upfront, up to 40 targets

2012

 
  • $40M equity financing

2011

  • Founded by Flagship Pioneering